CELU Add to watchlist $1.01 +0.02 (+1.92%) Last updated: May 31, 2026 08:38
52-Week Range
$1.01
$0.71 $1.01 $4.35

Fundamentals Overview

Celularity Inc. is near the low of its 52-week range with low valuation, trading relatively flat today.

Valuation low

P/S 0.92

Risk (Beta)

0.45 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 59% confidence Risk: Lower Volatility — Beta 0.45. Diversify and only invest what you can afford to lose.

Pressures (Sell):

Sentiment weakening (3 downgrades) · 3M vs S&P 500: -28.3% · 3M vs Healthcare sector: -13.9%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$24.29M
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$0.71 - $4.35
Volume vs Avg
N/A
Beta
0.45

About

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (...
Sector: Healthcare
Headquarters: US
Employees: 120
IPO Date: Aug 2019
Beta: 0.45 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: C. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 5, Equal Weight: 2, Hold: 2, Outperform: 1, Perform: 1, Underweight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-15.23; current price is $1.01. That’s a -1607.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) N/A
P/S (TTM) 0.92
Liquidity & enterprise
Current Ratio (TTM) 0.15
Quick Ratio (TTM) 0.15
Cash Ratio (TTM) 0.08
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -3.45%
Gross margin (TTM) 76.04%
Operating margin (TTM) -2.31%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for CELU.

Analyst Sentiment at a Glance

C Sentiment Weakening
Buy 5Equal Weight 2Hold 2Outperform 1Perform 1Underweight 1
1 upgrade, 3 downgrades
Consensus Target
$3.00
High Target
$3.00
Low Target
$3.00
Median Target
$3.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
WBB Securities upgrade Hold Buy 2025-09-09
Morgan Stanley downgrade Equal Weight Underweight 2023-01-29
HC Wainwright & Co. maintain Buy Buy 2023-01-29
Oppenheimer downgrade Outperform Perform 2022-12-21
Morgan Stanley maintain Equal Weight Equal Weight 2022-09-11
Alliance Global Partners maintain Buy Buy 2022-08-25
Truist Securities maintain Hold Hold 2022-08-22
HC Wainwright & Co. maintain Buy Buy 2022-06-22
Truist Securities downgrade Buy Hold 2022-04-05
Oppenheimer maintain Outperform Outperform 2022-01-28
Morgan Stanley maintain Equal Weight Equal Weight 2021-11-24
Truist Securities maintain Buy Buy 2021-10-19